Literature DB >> 6499900

Pharmacokinetics of metoprolol in healthy, elderly, non-smoking individuals after a single dose and two weeks of treatment.

M Larsson, S Landahl, P Lundborg, C G Regårdh.   

Abstract

The effect of long-term treatment on the absorption and disposition of metoprolol has been evaluated in 8 healthy, non-smoking, elderly individuals (mean age 74.5 years) and in a control group of 8 healthy, young individuals. Two trace doses of [3H]metoprolol were given i.v., first concomitantly with a single oral 50 mg dose of cold metoprolol, and second, with the morning dose after 2 weeks of treatment with 50 mg b.d. In the elderly, the mean AUC increased by about 45% (p less than 0.05) over the treatment period, while in the control group the mean AUC was 18% greater (p less than 0.05) on Day 14 than on Day 1. In the elderly, changes both in pre-systemic elimination and in total body clearance accounted for the elevation of the AUC, whereas reduced first-pass effect appeared to be the major cause of the increased steady-state plasma level in the control group. With the exception of the volume term, V beta, the pharmacokinetic parameters were not significantly different between the elderly and the young individuals. For this reason, almost identical steady-state plasma levels were attained in the two groups. The results suggest that age-related physiological changes may have some minor effects on the pharmacokinetics of metoprolol, and also that the changes do not lead to significantly altered plasma concentrations compared to those in young individuals.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6499900     DOI: 10.1007/bf00544048

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  19 in total

1.  Plasma metoprolol concentrations in young, old and hypertensive subjects.

Authors:  M J Kendall; D Brown; R A Yates
Journal:  Br J Clin Pharmacol       Date:  1977-08       Impact factor: 4.335

2.  Disposition of propranolol. V. Drug accumulation and steady-state concentrations during chronic oral administration in man.

Authors:  G H Evans; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1973 Jul-Aug       Impact factor: 6.875

3.  Pharmacokinetics and pharmacodynamics in young normal and elderly hypertensive subjects: a study using sotalol as a model drug.

Authors:  T Ishizaki; H Hirayama; K Tawara; H Nakaya; M Sato; K Sato
Journal:  J Pharmacol Exp Ther       Date:  1980-01       Impact factor: 4.030

4.  The effect of age on the pharmacokinetics of oxprenolol.

Authors:  M J Kendall; C P Quarterman
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1982-03

5.  Biological determinants of propranolol disposition in man.

Authors:  D M Kornhauser; A J Wood; R E Vestal; G R Wilkinson; R A Branch; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1978-02       Impact factor: 6.875

6.  A single and multiple dose pharmacokinetic and pharmacodynamic comparison of conventional and slow-release metroprolol.

Authors:  M J Kendall; V A John; C P Quarterman; P G Welling
Journal:  Eur J Clin Pharmacol       Date:  1980-02       Impact factor: 2.953

7.  Effect of age on plasma propranolol levels.

Authors:  R E Schneider; H Bishop; R A Yates; C P Quarterman; M J Kendall
Journal:  Br J Clin Pharmacol       Date:  1980-08       Impact factor: 4.335

8.  A comparison of numerical integrating algorithms by trapezoidal, Lagrange, and spline approximation.

Authors:  K C Yeh; K C Kwan
Journal:  J Pharmacokinet Biopharm       Date:  1978-02

9.  Plasma levels and effect on heart rate and blood pressure of metoprolol after acute oral administration in 12 geriatric patients.

Authors:  P Lundborg; B Steen
Journal:  Acta Med Scand       Date:  1976

10.  Selected ion monitoring of metoprolol and two metabolites in plasma and urine using deuterated internal standards.

Authors:  M Ervik; K J Hoffmann; K Kylberg-Hanssen
Journal:  Biomed Mass Spectrom       Date:  1981-07
View more
  12 in total

Review 1.  The use of modeling tools to drive efficient oral product design.

Authors:  Neil R Mathias; John Crison
Journal:  AAPS J       Date:  2012-05-30       Impact factor: 4.009

Review 2.  Hepatic drug metabolism and aging.

Authors:  C Durnas; C M Loi; B J Cusack
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

Review 3.  Pharmacokinetic Variability of Drugs Used for Prophylactic Treatment of Migraine.

Authors:  Peer Tfelt-Hansen; Frederik Nybye Ågesen; Agniezka Pavbro; Jacob Tfelt-Hansen
Journal:  CNS Drugs       Date:  2017-05       Impact factor: 5.749

4.  Prediction of modified release pharmacokinetics and pharmacodynamics from in vitro, immediate release, and intravenous data.

Authors:  Viera Lukacova; Walter S Woltosz; Michael B Bolger
Journal:  AAPS J       Date:  2009-05-09       Impact factor: 4.009

Review 5.  Pharmacokinetic and pharmacodynamic changes in the elderly. Clinical implications.

Authors:  A Hämmerlein; H Derendorf; D T Lowenthal
Journal:  Clin Pharmacokinet       Date:  1998-07       Impact factor: 6.447

Review 6.  Controlled release metoprolol formulations. A review of their pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and ischaemic heart disease.

Authors:  G L Plosker; S P Clissold
Journal:  Drugs       Date:  1992-03       Impact factor: 9.546

7.  Influence of smoking and gender on the disposition kinetics of metoprolol.

Authors:  L J Schaaf; S C Campbell; M B Mayersohn; T Vagedes; D G Perrier
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 8.  Individual variation in first-pass metabolism.

Authors:  Y K Tam
Journal:  Clin Pharmacokinet       Date:  1993-10       Impact factor: 6.447

Review 9.  Clinical pharmacokinetic considerations in the elderly. An update.

Authors:  S Dawling; P Crome
Journal:  Clin Pharmacokinet       Date:  1989-10       Impact factor: 6.447

Review 10.  Free drug metabolic clearance in elderly people.

Authors:  Jennifer M Butler; Evan J Begg
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.